Current and emerging pharmacotherapy for Gaucher disease in pediatric populations

References

• Weinreb NJ, Charrow J, Andersson HC. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med. 2002;113(2):112–119.
   PubMed Web of Science ®Google Scholar
• Seehra G, Solomon B, Ryan E. Five-parameter evaluation of dysphagia: a novel prognostic scale for assessing neurological decline in Gaucher disease type 2. Mol Genet Metab. 2019;127(3):191–199.
   PubMed Web of Science ®Google Scholar
• Roshan Lal T, Seehra GK, Steward AM, et al. The natural history of type 2 gaucher disease in the 21st century: a retrospective study. Neurology. 2020;95(15):e2119-e2130.
   PubMed Web of Science ®Google Scholar
• Schiffmann R, Sevigny J, Rolfs A, et al., The definition of neuronopathic gaucher disease. J Inherit Metab Dis. 43(5): 1056–1059. 2020.
   PubMed Web of Science ®Google Scholar
• Poffenberger CN, Inati S, Tayebi N, et al. EEG abnormalities in patients with chronic neuronopathic gaucher disease: a retrospective review. Mol Genet Metab. 2020;131(3):358–363.
   PubMed Web of Science ®Google Scholar
• Gaucher Disease: SE. Insights from a Rare Mendelian Disorder. Discov Med. 2012;14(77):273–281.
   PubMed Web of Science ®Google Scholar
• Hughes D, Mikosch P, Belmatoug N. Gaucher disease in bone: from pathophysiology to practice. J Bone Min Res. 2019;34(6):996–1013.
   PubMed Web of Science ®Google Scholar
• Kauli R, Zaizov R, Lazar L, et al. Delayed growth and puberty in patients with Gaucher disease type 1: natural history and effect of splenectomy and/or enzyme replacement therapy. Isr Med Assoc J. 2000;2(2):158–163.
   PubMed Web of Science ®Google Scholar
• Nalysnyk L, Rotella P, Simeone JC, et al. Gaucher disease epidemiology and natural history: a comprehensive review of the literature. Hematology. 2017;22(2):65–73.
   PubMed Web of Science ®Google Scholar
• Charrow J, Andersson HC, Kaplan P, et al., The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med. 160(18): 2835–2843. 2000.
   PubMed Web of Science ®Google Scholar
• Jeong SY, Park SJ, Kim HJ. Clinical and genetic characteristics of Korean patients with Gaucher disease. Blood Cells Mol Dis. 2011;46(1):11–14.
   PubMed Web of Science ®Google Scholar
• Tylki-Szymanska A, Vellodi A, El-Beshlawy A, et al., Neuronopathic Gaucher disease: demographic and clinical features of 131 patients enrolled in the international collaborative gaucher group neurological outcomes subregistry. J Inherit Metab Dis. 33(4): 339–346. 2010.
   PubMed Web of Science ®Google Scholar
• Barton NW, Brady RO, Dambrosia JM. Replacement therapy for inherited enzyme deficiency–macrophage-targeted glucocerebrosidase for Gaucher’s disease. N Engl J Med. 1991;324(21):1464–1470.
   PubMed Web of Science ®Google Scholar
• Cox T, Lachmann R, Hollak C. Novel oral treatment of Gaucher’s disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet [ London, England]. 2000;355(9214):1481–1485.
   Web of Science ®Google Scholar
• Aflaki E, Westbroek W, Sidransky E. The complicated relationship between Gaucher disease and parkinsonism: insights from a rare disease. Neuron. 2017;93(4):737–746.
   PubMed Web of Science ®Google Scholar
• Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in parkinson’s disease. N Engl J Med. 2009;361(17):1651–1661.
   PubMed Web of Science ®Google Scholar
• Nalls MA, Duran R, Lopez G, et al. A multicenter study of glucocerebrosidase mutations in dementia with lewy bodies. JAMA Neurol. 2013;70(6):727–735.
   PubMed Web of Science ®Google Scholar
• Grabowski GA, Petsko GA, Kolodny EH, et al. Gaucher disease. In: Valle D, Al B, Vogelstein B, editors. Online Metab Mol Bases Inherit Dis. New York, NY: McGraw Hill; 2011. [cited 2021 Mar 22]. Available from: https://ommbid-mhmedical-com.ezproxy.nihlibrary.nih.gov/content.aspx?bookid=2709§ionid=225546056
   Google Scholar
• Kaplan P, Andersson HC, Kacena KA, et al., The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis. Arch Pediatr Adolesc Med. 160(6): 603–608. 2006.
   PubMed Web of Science ®Google Scholar
• Charrow J, Andersson HC, Kaplan P, et al. Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations. J Pediatr. 2004;144(1):112–120.
   PubMed Web of Science ®Google Scholar
• Weinreb NJ, Deegan P, Kacena KA, et al. Life expectancy in Gaucher disease type 1. Am J Hematol. 2008;83:896–900.
   PubMed Web of Science ®Google Scholar
• Maas M, Hangartner T, Mariani G, et al. Recommendations for the assessment and monitoring of skeletal manifestations in children with Gaucher disease. Skelet Radiol. 2008;37(3):185–188.
   PubMed Web of Science ®Google Scholar
• Grabowski GA, Andria G, Baldellou A, et al. Pediatric non-neuronopathic Gaucher disease: presentation, diagnosis and assessment. Consens Statements Eur J Pediatr. 2004;163(2):58–66.
   Google Scholar
• Andrade-Campos M, Alfonso P, Irun P, et al. Diagnosis features of pediatric Gaucher disease patients in the era of enzymatic therapy, a national-based study from the Spanish registry of gaucher disease. Orphanet J Rare Dis. 2017;12(1):84.
   PubMedGoogle Scholar
• Katz K, Mechlis-Frish S, Cohen IJ, et al. Bone scans in the diagnosis of bone crisis in patients who have Gaucher disease. J Bone Jt Surg Am. 1991;73(4):513–517.
   PubMedGoogle Scholar
• Elstein D, Abrahamov A, Dweck A, et al. Gaucher disease: pediatric concerns. Paediatr Drugs. 2002;4(7):417–426.
   PubMedGoogle Scholar
• Brady RO, Barton NW, Grabowski GA. The role of neurogenetics in Gaucher disease. Arch Neurol. 1993;50(11):1212–1224.
   PubMedGoogle Scholar
• Kaplan P, Baris H, De Meirleir L, et al., Revised recommendations for the management of Gaucher disease in children. Eur J Pediatr. 172(4): 447–458. 2013.
   PubMed Web of Science ®Google Scholar
• Yang AC, Bier L, Overbey JR, et al., Early manifestations of type 1 Gaucher disease in presymptomatic children diagnosed after parental carrier screening. Genet Med. 19(6): 652–658. 2017.
   PubMed Web of Science ®Google Scholar
• Newborn AS. Screening for lysosomal storage disorders. J Pediatr Health Care. 2018;32(3):285–294.
   PubMed Web of Science ®Google Scholar
• Revel-Vilk S, Szer J, Mehta A, et al., How we manage Gaucher disease in the era of choices. Br J Haematol. 182(4): 467–480. 2018.
   PubMed Web of Science ®Google Scholar
• Degnan AJ, Ho-Fung VM, Ahrens-Nicklas RC, et al. Imaging of non-neuronopathic Gaucher disease: recent advances in quantitative imaging and comprehensive assessment of disease involvement. Insights Imaging [Internet]. 2019 [cited 2021 Mar 4];10. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6616606/.
   Google Scholar
• Petros M. Revisiting the Wilson-Jungner criteria: how can supplemental criteria guide public health in the era of genetic screening? Genet Med. 2012;14(1):129–134.
   PubMed Web of Science ®Google Scholar
• Therrell BL, Padilla CD, Loeber JG, et al., Current status of newborn screening worldwide: 2015. Semin Perinatol. 39(3): 171–187. 2015.
   PubMed Web of Science ®Google Scholar
• Wasserstein MP, Caggana M, Bailey SM, et al. The New York pilot newborn screening program for lysosomal storage diseases: report of the First 65,000 Infants. Genet Med. 2019;21(3):631–640.
   PubMed Web of Science ®Google Scholar
• Spada M, Pagliardini S, Yasuda M, et al. High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet. 2006;79(1):31–40.
   PubMed Web of Science ®Google Scholar
• Chien YH, Chiang SC, Zhang XK, et al. Early detection of pompe disease by newborn screening is feasible: results from the Taiwan screening program. Pediatrics. 2008;122(1):39–45.
   PubMed Web of Science ®Google Scholar
• Liao HC, Chiang CC, Niu DM, et al. Detecting multiple lysosomal storage diseases by tandem mass spectrometry–a national newborn screening program in Taiwan. Clin Chim Acta. 2014;431:80–86.
   PubMed Web of Science ®Google Scholar
• Kemper AR, Hwu WL, Lloyd-Puryear M, et al. Newborn screening for pompe disease: synthesis of the evidence and development of screening recommendations. Pediatrics. 2007;120(5):1327–1334.
   Web of Science ®Google Scholar
• Sanders KA, Gavrilov DK, Oglesbee D, et al. A comparative effectiveness study of newborn screening methods for four lysosomal storage disorders. Int J Neonatal Screen. 2020;6(2):6.
   PubMed Web of Science ®Google Scholar
• Hopkins PV, Campbell C, Klug T, et al. Lysosomal storage disorder screening implementation: findings from the first six months of full population pilot testing in Missouri. J Pediatr. 2015;166(1):172–177.
   PubMed Web of Science ®Google Scholar
• Burton BK, Charrow J, Hoganson GE, et al. Newborn Screening for Lysosomal Storage Disorders in Illinois: the Initial 15-Month Experience. J Pediatr. 2017;190:130–135.
   PubMed Web of Science ®Google Scholar
• Elliott S, Buroker N, Cournoyer JJ, et al. Pilot study of newborn screening for six lysosomal storage diseases using Tandem Mass Spectrometry. Mol Genet Metab. 2016;118(4):304–309.
   PubMed Web of Science ®Google Scholar
• Hopkins PV, Klug T, Vermette L, et al. Incidence of 4 Lysosomal Storage Disorders From 4 Years of Newborn Screening. JAMA Pediatr. 2018;172(7):696–697.
   PubMed Web of Science ®Google Scholar
• Lisi EC, McCandless SE. Newborn Screening for Lysosomal Storage Disorders: views of Genetic Healthcare Providers. J Genet Couns. 2016;25(2):373–384.
   PubMed Web of Science ®Google Scholar
• Elstein D, Abrahamov A, Itzchaki M, et al. Commentary: low-dose high-frequency enzyme replacement therapy prevents fractures without complete suppression of painful bone crises in patients with severe juvenile onset type I Gaucher disease. Blood Cells Mol Dis. 1998;24(306–308):303–305.
   PubMedGoogle Scholar
• Bembi B, Ciana G, Mengel E, et al. Bone complications in children with Gaucher disease. Br J Radiol. 2002;75(Suppl 1):37–44.
   Google Scholar
• Kaplan P, Mazur A, Manor O, et al. Acceleration of retarded growth in children with Gaucher disease after treatment with alglucerase. J Pediatr. 1996;129(1):149–153.
   PubMed Web of Science ®Google Scholar
• Zevin S, Abrahamov A, Hadas-Halpern I, et al. Adult-type Gaucher disease in children: genetics, clinical features and enzyme replacement therapy. Q J Med. 1993;86(9):565–573.
   PubMedGoogle Scholar
• Damiano AM, Pastores GM, Ware JE. The health-related quality of life of adults with Gaucher’s disease receiving enzyme replacement therapy: results from a retrospective study. Qual Life Res. 1998;7(5):373–386.
   PubMed Web of Science ®Google Scholar
• Wilson AC, Palermo TM. Physical activity and function in adolescents with chronic pain: a controlled study using actigraphy. J Pain. 2012;13(2):121–130.
   PubMed Web of Science ®Google Scholar
• Alioto AG, Gomez R, Moses J, et al. Quality of life and psychological functioning of pediatric and young adult patients with Gaucher disease, type 1. Am J Med Genet A. 2020;182(5):1130–1142.
   PubMed Web of Science ®Google Scholar
• Remor E, Baldellou A. Health-related quality of life in children and adolescents living with Gaucher disease and their parents. Health Psychol Behav Med. 2018;6(1):79–92.
   PubMed Web of Science ®Google Scholar
• Kallish S, Kaplan P. A disease severity scoring system for children with type 1 Gaucher disease. Eur J Pediatr. 2013;172(1):39–43.
   PubMed Web of Science ®Google Scholar
• Davies EH, Mengel E, Tylki-Szymanska A, et al. Four-year follow-up of chronic neuronopathic Gaucher disease in Europeans using a modified severity scoring tool. J Inherit Metab Dis. 2011;34(5):1053–1059.
   PubMed Web of Science ®Google Scholar
• Revel-Vilk S, Fuller M, Zimran A. Value of glucosylsphingosine (Lyso-Gb1) as a biomarker in Gaucher disease: a systematic literature review. Int J Mol Sci. 2020;21(19):7159.
   Web of Science ®Google Scholar
• Raskovalova T, Deegan PB, Mistry PK, et al. Accuracy of chitotriosidase activity and CCL18 concentration in assessing type I Gaucher disease severity. A systematic review with meta-analysis of individual participant data. Haematologica [Internet]. 2020 [cited 2021 Jan 2]; Available from: https://haematologica.org/article/view/9633.
   Google Scholar
• Boot RG, Renkema GH, Verhoek M, et al. The human chitotriosidase gene. Nature of inherited enzyme deficiency. J Biol Chem. 1998;273(40):25680–25685.
   PubMed Web of Science ®Google Scholar
• Aerts JMFG, Kallemeijn WW, Wegdam W, et al. Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies. J Inherit Metab Dis. 2011;34(3):605–619.
   PubMed Web of Science ®Google Scholar
• Orvisky E, Park JK, LaMarca ME, et al. Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: correlation with phenotype and genotype. Mol Genet Metab. 2002;76(4):262–270.
   PubMed Web of Science ®Google Scholar
• Hurvitz N, Dinur T, Cohen MB, et al. Glucosylsphingosine (Lyso-gb1) as a biomarker for monitoring treated and untreated children with gaucher disease. Int J Mol Sci. 2019;20(12):20.
   Web of Science ®Google Scholar
• Cozma C, Cullufi P, Kramp G, et al. Treatment efficiency in gaucher patients can reliably be monitored by quantification of lyso-gb1 concentrations in dried blood spots. Int J Mol Sci [Internet]. 2020 [cited 2021 Jan 2];21. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369829/.
   Google Scholar
• Menkovic I, Boutin M, Alayoubi A, et al. Identification of a reliable biomarker profile for the diagnosis of gaucher disease type 1 patients using a mass spectrometry-based metabolomic approach. Int J Mol Sci. Internet]. 2020 [cited 2021 Jan 2];21. Available from. ;. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7660648/
   Web of Science ®Google Scholar
• Tang C, Jia X, Tang F, et al. Detection of glucosylsphingosine in dried blood spots for diagnosis of Gaucher disease by LC-MS/MS. Clin Biochem. 2021;87:79–84.
   PubMed Web of Science ®Google Scholar
• Mistry PK, Lopez G, Schiffmann R, et al., Gaucher disease: progress and ongoing challenges. Mol Genet Metab. 120(1–2): 8–21. 2017.
   PubMedGoogle Scholar
• Krasnewich D, Dietrich K, Bauer L, et al. Splenectomy in Gaucher disease: new management dilemmas. Blood. 1998;91(8):3085–3087.
   PubMed Web of Science ®Google Scholar
• Tsai P, Lipton JM, Sahdev I, et al. Allogenic bone marrow transplantation in severe Gaucher disease. Pediatr Res. 1992;31(5):503–507.
   PubMed Web of Science ®Google Scholar
• Rappeport JM, Ginns EI. Bone-marrow transplantation in severe Gaucher’s disease. N Engl J Med. 1984;311(2):84–88.
   PubMed Web of Science ®Google Scholar
• Ringdén O, Groth CG, Erikson A, et al. Ten years’ experience of bone marrow transplantation for Gaucher disease. Transplantation. 1995;59(6):864–870.
   PubMed Web of Science ®Google Scholar
• Brady RO, Kanfer JN, Shapiro D. Metabolism of glucocerebrosides II. Evidence of an enzymatic deficiency in Gaucher’s disease. Biochem Biophys Res Commun. 1965;18(2):221–225.
   PubMed Web of Science ®Google Scholar
• Ries M. Enzyme replacement therapy and beyond—in memoriam Roscoe O. Brady, M.D. (1923–2016). J Inherit Metab Dis. 2017;40(3):343–356.
   PubMed Web of Science ®Google Scholar
• Neufeld EF. Enzyme replacement therapy – a brief history. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry Dis Perspect 5 Years FOS [Internet]. Oxford: Oxford PharmaGenesis;2006. [cited 2020 Oct 23]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK11588/
   Google Scholar
• Burrow TA, Grabowski GA. Velaglucerase alfa in the treatment of Gaucher disease type 1. Clin Investig. 2011;1(2):285–293.
   Google Scholar
• Zimran A, Brill-Almon E, Chertkoff R, et al. Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood. 2011;118(22):5767–5773.
   PubMed Web of Science ®Google Scholar
• Rosenthal DI, Doppelt SH, Mankin HJ, et al. Enzyme replacement therapy for Gaucher disease: skeletal responses to macrophage-targeted glucocerebrosidase. Pediatrics. 1995;96(4 Pt 1):629–637.
   PubMed Web of Science ®Google Scholar
• Poll LW, Maas M, Terk MR, et al. Response of Gaucher bone disease to enzyme replacement therapy. Br J Radiol. 2002;75(Suppl 1):A25–36.
   PubMedGoogle Scholar
• Gupta P, Pastores G. Pharmacological treatment of pediatric Gaucher disease. Expert Rev Clin Pharmacol. 2018;11(12):1183–1194.
   PubMed Web of Science ®Google Scholar
• Stone DL, Ginns EI, Krasnewich D, et al. Life-threatening splenic hemorrhage in two patients with Gaucher disease. Am J Hematol. 2000;64(2):140–142.
   PubMed Web of Science ®Google Scholar
• Qiu Z, Zhang B, Song Y, et al. Maintenance efficacy of low dose imiglucerase for gaucher disease [internet]. PREPRINT; 2020 [ cited 2021 Jan 3]. Available from: https://www.researchsquare.com/article/rs-25075/v1.
   Google Scholar
• Potnis KC, Flueckinger LB, Ha CI, et al. Bone manifestations in neuronopathic Gaucher disease while receiving high-dose enzyme replacement therapy. Mol Genet Metab. 2019;126(2):157–161.
   PubMed Web of Science ®Google Scholar
• Fost M de, Noesel CJM van, Aerts JMFG, et al. Persistent bone disease in adult type. 1 Gaucher disease despite increasing doses of enzyme replacement therapy. Haematologica. 2008;93(7):1119–1120.
   PubMed Web of Science ®Google Scholar
• Deegan PB, Pavlova E, Tindall J, et al. Osseous manifestations of adult Gaucher disease in the era of enzyme replacement therapy. Medicine (Baltimore). 2011;90(1):52–60.
   PubMed Web of Science ®Google Scholar
• Andrade-Campos M, Escuder-Azuara B, De Frutos LL, et al. Direct and indirect effects of the SARS-CoV-2 pandemic on Gaucher disease patients in Spain: TIME to reconsider home-based therapies? Blood Cells Mol Dis. 2020;85:102478.
   PubMed Web of Science ®Google Scholar
• Mistry P, Balwani M, Barbouth D, et al. Gaucher disease and SARS-CoV-2 infection: emerging management challenges. Mol Genet Metab. 2020;130(3):164–169.
   PubMed Web of Science ®Google Scholar
• Fierro L, Nesheiwat N, Naik H, et al. Gaucher disease and SARS-CoV-2 infection: experience from 181 patients in New York. Mol Genet Metab [Internet]. 2020 [cited 2021 Jan 3]; Available from: http://www.sciencedirect.com/science/article/pii/S1096719220305576.
   Google Scholar
• Zimran A, Goldblatt J, Szer J. Should eliglustat be first line therapy for patients with type 1 Gaucher disease? Definitions of safety and efficacy. Blood Cells Mol Dis. 2018;68:14–16.
   PubMed Web of Science ®Google Scholar
• Goldblatt J, Fletcher JM, McGill J, et al. Enzyme replacement therapy “drug holiday”: results from an unexpected shortage of an orphan drug supply in Australia. Blood Cells Mol Dis. 2011;46(1):107–110.
   PubMed Web of Science ®Google Scholar
• McCormack PL, Goa KL. Miglustat. Drugs. 2003;63(22):2427–2434.
   PubMed Web of Science ®Google Scholar
• DailyMed - ZAVESCA- miglustat capsule [Internet]. [cited 2021 Jan 3]. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=817892d1-ee12-4632-85fc-57ccdf16d7b8.
   Google Scholar
• Bennett LL, Mohan D. Gaucher disease and its treatment options. Ann Pharmacother. 2013;47(9):1182–1193.
   PubMed Web of Science ®Google Scholar
• Bennett LL, Turcotte K. Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease. Drug Des Devel Ther. 2015;9:4639–4647.
   PubMed Web of Science ®Google Scholar
• Limgala RP, Goker-Alpan O Effect of substrate reduction therapy in comparison to enzyme replacement therapy on immune aspects and bone involvement in gaucher disease. Biomolecules [Internet]. 2020 [cited 2021 Jan 3];10. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226435/.
   Google Scholar
• Goker-Alpan O. Optimal therapy in Gaucher disease. Ther Clin Risk Manag. 2010;6:315–323.
   PubMed Web of Science ®Google Scholar
• Balwani M, Burrow TA, Charrow J, et al. Recommendations for the use of eliglustat in the treatment of adults with Gaucher disease type 1 in the United States. Mol Genet Metab. 2016;117(2):95–103.
   PubMed Web of Science ®Google Scholar
• Sanofi. Open label, two cohort (with and without imiglucerase), multicenter study to evaluate pharmacokinetics, safety, and efficacy of eliglustat in pediatric patients with gaucher disease type 1 and type 3 [internet]. clinicaltrials.gov; 2020 [cited 2020 Dec 30]. Report No.: NCT03485677. Available from: https://clinicaltrials.gov/ct2/show/NCT03485677.
   Google Scholar
• Zavesca (miglustat) 100 mg hard capsules - summary of product characteristics (smpc) - (emc) [internet]. [ cited 2021 Mar 5]. Available from: https://www.medicines.org.uk/emc/product/39/smpc.
   Google Scholar
• Genzyme, a sanofi company. 3-part study to evaluate the efficacy and safety of venglustat in combination with cerezyme in adult and pediatric patients with gaucher disease type 3 (gd3) with open-label long-term treatment [internet]. clinicaltrials.gov; 2020 [cited 2020 Dec 30]. Report No.: NCT02843035. Available from: https://clinicaltrials.gov/ct2/show/NCT02843035.
   Google Scholar
• Schiffmann R, Cox TM, Dedieu J Venglustat combined with imiglucerase positively affects neurological features and brain connectivity in adults with Gaucher disease type 3. Abstract −17th Annual WORLDSymposium, 2021 February 8th-12th. Molecular Genetics and Metabolism 2021;132;S95.
   Google Scholar
• Jung O, Patnaik S, Marugan J, et al., Progress and potential of non-inhibitory small molecule chaperones for the treatment of Gaucher disease and its implications for Parkinson’s disease. Expert Rev Proteomics. 13(5): 471–479. 2016.
   PubMed Web of Science ®Google Scholar
• Maegawa GHB, Tropak MB, Buttner JD, et al. Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease. J Biol Chem. 2009;284(35):23502–23516.
   PubMed Web of Science ®Google Scholar
• Shaare zedek medical center. Ambroxol therapy for patients with type 1 gaucher disease and suboptimal response to enzyme replacement therapy [internet]. clinicaltrials.gov; 2019 [cited 2020 Dec 30]. Report No.: NCT03950050. Available from: https://clinicaltrials.gov/ct2/show/NCT03950050.
   Google Scholar
• Mullin S, Smith L, Lee K, et al. Ambroxol for the treatment of patients with Parkinson disease with and without glucocerebrosidase gene mutations: a nonrandomized, noncontrolled trial. JAMA Neurol. 2020;77(4):427–434.
   PubMed Web of Science ®Google Scholar
• Kim Y-M, Yum M-S, Heo SH, et al. Pharmacologic properties of high-dose ambroxol in four patients with Gaucher disease and myoclonic epilepsy. J Med Genet. 2020;57(2):124–131.
   PubMed Web of Science ®Google Scholar
• Narita A, Shirai K, Itamura S, et al. Ambroxol chaperone therapy for neuronopathic Gaucher disease: a pilot study. Ann Clin Transl Neurol. 2016;3(3):200–215.
   PubMed Web of Science ®Google Scholar
• Jiang W, Yi M, Maegawa GHB, et al. Ambroxol improves skeletal and hematological manifestations on a child with Gaucher disease. J Hum Genet. 2020;65(3):345–349.
   PubMed Web of Science ®Google Scholar
• Charkhand B, Scantlebury MH, Narita A, et al. Effect of Ambroxol chaperone therapy on Glucosylsphingosine (Lyso-Gb1) levels in two Canadian patients with type 3 Gaucher disease. Mol Genet Metab Rep. 2019;20:100476.
   PubMed Web of Science ®Google Scholar
• Chu S-Y, Chien -C-C, Hwu W-L, et al. Early initiation of high-dose oral ambroxol in combination with enzyme replacement therapy in a neuropathic Gaucher infant. Blood Cells Mol Dis. 2020;81:102402.
   PubMed Web of Science ®Google Scholar
• Ciana G, Dardis A, Pavan E, et al. In vitro and in vivo effects of ambroxol chaperone therapy in two Italian patients affected by neuronopathic Gaucher disease and epilepsy. Mol Genet Metab Rep. 2020;25:100678.
   PubMed Web of Science ®Google Scholar
• Pawlinski L, Krawczyk M, Fiema M, et al. Dual-action ambroxol in treatment of chronic pain in Gaucher Disease. Eur J Pain. 2020;24(5):992–996.
   PubMed Web of Science ®Google Scholar
• Steet RA, Chung S, Wustman B, et al. The iminosugar isofagomine increases the activity of N370S mutant acid β-glucosidase in Gaucher fibroblasts by several mechanisms. Proc Natl Acad Sci. 2006;103(37):13813–13818.
   PubMed Web of Science ®Google Scholar
• Amicus therapeutics announces preliminary results of phase 2 study with plicera(TM) for gaucher disease | amicus therapeutics [internet]. [ cited 2021 Jan 3]. Available from: https://ir.amicusrx.com/news-releases/news-release-details/amicus-therapeutics-announces-preliminary-results-phase-2-study.
   Google Scholar
• Yang C, Rahimpour S, Lu J, et al. Histone deacetylase inhibitors increase glucocerebrosidase activity in Gaucher disease by modulation of molecular chaperones. Proc Natl Acad Sci. 2013;110(3):966–971.
   PubMed Web of Science ®Google Scholar
• Goldin E, Zheng W, Motabar O, et al. High throughput screening for small molecule therapy for Gaucher disease using patient tissue as the source of mutant glucocerebrosidase. PLoS One. 2012;7(1):e29861.
   PubMed Web of Science ®Google Scholar
• Aflaki E, Stubblefield BK, Maniwang E, et al. Macrophage models of Gaucher disease for evaluating disease pathogenesis and candidate drugs. Sci Transl Med. 2014;6(240):240ra73.
   PubMed Web of Science ®Google Scholar
• Aflaki E, Borger DK, Moaven N, et al. A New Glucocerebrosidase chaperone reduces α-synuclein and glycolipid levels in iPSC-derived dopaminergic neurons from patients with Gaucher disease and parkinsonism. J Neurosci. 2016;36(28):7441–7452.
   PubMed Web of Science ®Google Scholar
• Burbulla LF, Jeon S, Zheng J, et al. A modulator of wild-type glucocerebrosidase improves pathogenic phenotypes in dopaminergic neuronal models of Parkinson’s disease. Sci Transl Med. 2019;11(514):11.
   Web of Science ®Google Scholar
• Zheng J, Chen L, Skinner OS, et al. β-Glucocerebrosidase modulators promote dimerization of β-Glucocerebrosidase and reveal an allosteric binding site. J Am Chem Soc. 2018;140(18):5914–5924.
   PubMed Web of Science ®Google Scholar
• Fog-Tonnesen CK, Zago P, Malini E, et al. Arimoclomol as a potential therapy for neuronopathic Gaucher Disease. bioRxiv. 2018;281824.
   Google Scholar
• Goasdoué K, Miller SM, Colditz PB, et al. Review: the blood-brain barrier; protecting the developing fetal brain. Placenta. 2017;54:111–116.
   PubMed Web of Science ®Google Scholar
• Nguyen Q-H, Witt RG, Wang B, et al. Tolerance induction and microglial engraftment after fetal therapy without conditioning in mice with mucopolysaccharidosis type VII. Sci Transl Med. Internet]. 2020 [cited 2021 Jan 3];12. Available from; (532): eaay8980. https://stm.sciencemag.org/content/12/532/eaay8980.
   Web of Science ®Google Scholar
• UCSF. UCSF mucopolysaccharidosis trial: in utero enzyme replacement therapy for lysosomal storage diseases [internet]. [cited 2021 Jan 3]. Available from: https://clinicaltrials.ucsf.edu/trial/NCT04532047.
   Google Scholar
• Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet. 2003;4(5):346–358.
   PubMed Web of Science ®Google Scholar
• Nakai H, Storm TA, Kay MA. Increasing the size of rAAV-mediated expression cassettes in vivo by intermolecular joining of two complementary vectors. Nat Biotechnol. 2000;18(5):527–532.
   PubMed Web of Science ®Google Scholar
• Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019;18:358–378.
   PubMed Web of Science ®Google Scholar
• Massaro G, Mattar CNZ, Wong AMS, et al. Fetal gene therapy for neurodegenerative disease of infants. Nat Med. 2018;24(9):1317–1323.
   PubMed Web of Science ®Google Scholar
• Prevail Therapeutics. An open-label, phase 1/2 study to evaluate the safety and efficacy of single-dose pr001a in infants with type 2 gaucher disease [internet]. clinicaltrials.gov; 2020 [cited 2020 Dec 30]. Report No.: NCT04411654. Available from: https://clinicaltrials.gov/ct2/show/NCT04411654.
   Google Scholar
• AvroBio. An adaptive, open-label, multinational phase 1/2 study of the safety and efficacy of ex vivo, lentiviral vector-mediated gene therapy avr-rd-02 for subjects with type 1 gaucher disease [internet]. clinicaltrials.gov; 2020 [cited 2020 Jun 1]. Report No.: NCT04145037. Available from: https://clinicaltrials.gov/ct2/show/NCT04145037.
   Google Scholar
• Miranda CJ, Canavese M, Chisari E, et al. Liver-directed aav gene therapy for gaucher disease. Blood. 2019;134(Supplement_1):3354.
   Google Scholar
• Sun Y, Liou B, Chu Z, et al. Systemic enzyme delivery by blood-brain barrier-penetrating SapC-DOPS nanovesicles for treatment of neuronopathic Gaucher disease. EBioMedicine. 2020;55:102735.
   PubMed Web of Science ®Google Scholar
• Research C for DE and. pediatric rare diseases–a collaborative approach for drug development using gaucher disease as a model; draft guidance for industry [internet]. US Food Drug Adm. FDA; 2020 [cited 2021 Jan 3]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pediatric-rare-diseases-collaborative-approach-drug-development-using-gaucher-disease-model-draft.
   Google Scholar
• Frcp Jvamp MDSJY, editors. Neonatal and pediatric pharmacology: therapeutic principles in practice. Philadelphia; 2010.
   Google Scholar
• Leeder JS. Translating pharmacogenetics and pharmacogenomics into drug development for clinical pediatrics and beyond. Drug Discov Today. 2004;9(13):567–573.
   PubMed Web of Science ®Google Scholar
• Almeida-Porada G, Waddington SN, Chan JKY, et al. In utero gene therapy consensus statement from the IFeTIS. Mol Ther J Am Soc Gene Ther. 2019;27(4):705–707.
   PubMed Web of Science ®Google Scholar
• Botkin JR, Belmont JW, Berg JS, et al. Points to consider: ethical, legal, and psychosocial implications of genetic testing in children and adolescents. Am J Hum Genet. 2015;97(1):6–21.
   PubMed Web of Science ®Google Scholar
• Buckland KF, Bobby Gaspar H. Gene and cell therapy for children — new medicines, new challenges? Adv Drug Deliv Rev. 2014;73:162–169.
   PubMed Web of Science ®Google Scholar